The Evidence of the Bystander Effect after Bleomycin Electrotransfer and Irreversible Electroporation.
bleomycin
bystander effect
electroablation
electrochemotherapy
electroporation
electrotransfer
irreversible electroporation
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
02 Oct 2021
02 Oct 2021
Historique:
received:
07
08
2021
revised:
16
09
2021
accepted:
24
09
2021
entrez:
13
10
2021
pubmed:
14
10
2021
medline:
19
11
2021
Statut:
epublish
Résumé
One of current applications of electroporation is electrochemotherapy and electroablation for local cancer treatment. Both of these electroporation modalities share some similarities with radiation therapy, one of which could be the bystander effect. In this study, we aimed to investigate the role of the bystander effect following these electroporation-based treatments. During direct CHO-K1 cell treatment, cells were electroporated using one 100 µs duration square wave electric pulse at 1400 V/cm (for bleomycin electrotransfer) or 2800 V/cm (for irreversible electroporation). To evaluate the bystander effect, the medium was taken from directly treated cells after 24 h incubation and applied on unaffected cells. Six days after the treatment, cell viability and colony sizes were evaluated using the cell colony formation assay. The results showed that the bystander effect after bleomycin electrotransfer had a strong negative impact on cell viability and cell colony size, which decreased to 2.8% and 23.1%, respectively. On the contrary, irreversible electroporation induced a strong positive bystander effect on cell viability, which increased to 149.3%. In conclusion, the results presented may serve as a platform for further analysis of the bystander effect after electroporation-based therapies and may ultimately lead to refined application of these therapies in clinics.
Identifiants
pubmed: 34641546
pii: molecules26196001
doi: 10.3390/molecules26196001
pmc: PMC8512684
pii:
doi:
Substances chimiques
Alarmins
0
Reactive Oxygen Species
0
Bleomycin
11056-06-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Lietuvos Mokslo Taryba
ID : S-MIP-19-13
Références
Cancer Immunol Res. 2014 Dec;2(12):1125-31
pubmed: 25480554
Mol Cancer. 2021 Jan 4;20(1):2
pubmed: 33390169
Arch Biochem Biophys. 2019 May 15;666:156-160
pubmed: 30543787
Biochim Biophys Acta. 1999 Nov 9;1461(1):123-34
pubmed: 10556494
Sci Rep. 2019 Jun 24;9(1):9094
pubmed: 31235753
J Nat Prod. 2000 Jan;63(1):158-68
pubmed: 10650103
Nat Commun. 2019 Feb 22;10(1):899
pubmed: 30796212
J Eur Acad Dermatol Venereol. 2018 Jul;32(7):1147-1154
pubmed: 29178483
Cancer Lett. 2015 Jan 1;356(1):105-13
pubmed: 24139966
Nucleic Acids Res. 2008 Jun;36(11):3781-90
pubmed: 18492718
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818785329
pubmed: 29986632
Sci Rep. 2021 Jan 14;11(1):1423
pubmed: 33446750
Curr Top Med Chem. 2021;21(5):404-425
pubmed: 32543358
Rep Pract Oncol Radiother. 2014 Aug 28;20(1):12-21
pubmed: 25535579
Radiother Oncol. 1996 Aug;40(2):121-5
pubmed: 8884965
J Membr Biol. 2016 Oct;249(5):703-711
pubmed: 27371159
Apoptosis. 2017 Nov;22(11):1321-1335
pubmed: 28936716
Radiology. 2020 May;295(2):254-272
pubmed: 32208094
Oncoimmunology. 2014 Apr 15;3:e28131
pubmed: 25083316
Molecules. 2020 Dec 31;26(1):
pubmed: 33396317
Nat Rev Immunol. 2020 Feb;20(2):95-112
pubmed: 31558839
Adv Drug Deliv Rev. 2017 Jan 15;109:1-2
pubmed: 28189183
Biomed Eng Online. 2013 Feb 21;12:16
pubmed: 23433433
Bioelectrochemistry. 2018 Feb;119:76-83
pubmed: 28917184
Redox Biol. 2019 Jul;25:101084
pubmed: 30612957
Bioelectrochemistry. 2020 Oct;135:107550
pubmed: 32450281
Acta Oncol. 2018 Jul;57(7):874-882
pubmed: 29577784
Clin Ther. 2020 Aug;42(8):1535-1548.e2
pubmed: 32768246
Immunol Today. 2000 Sep;21(9):418-20
pubmed: 10953090
Curr Pharm Des. 2012;18(23):3406-15
pubmed: 22663554
BMC Cancer. 2020 May 26;20(1):474
pubmed: 32456685
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Arch Dermatol. 2008 Sep;144(9):1186-8
pubmed: 18794464
Int J Mol Sci. 2019 Aug 19;20(16):
pubmed: 31430949
Immune Netw. 2018 Aug 13;18(4):e27
pubmed: 30181915
Cell Cycle. 2007 Jan 1;6(1):70-4
pubmed: 17245109
Eur J Immunol. 2011 May;41(5):1203-17
pubmed: 21523780
Expert Opin Biol Ther. 2012 Mar;12(3):275-86
pubmed: 22339479
Cell Death Dis. 2013 May 16;4:e631
pubmed: 23681226
Anticancer Drugs. 1998 Apr;9(4):319-25
pubmed: 9635922
Clin Exp Metastasis. 2013 Dec;30(8):1033-45
pubmed: 23832763
Adv Anat Embryol Cell Biol. 2017;227:59-71
pubmed: 28980040
J Membr Biol. 2015 Oct;248(5):857-63
pubmed: 26077843
J Cancer Res Ther. 2014 Oct-Dec;10(4):819-33
pubmed: 25579514
Mutat Res. 2013 Jan-Feb;741-742:35-43
pubmed: 23454491
Adv Immunol. 1994;56:1-26
pubmed: 8073945
PLoS One. 2014 Mar 19;9(3):e92444
pubmed: 24647355
Cancer Lett. 2015 Jan 1;356(1):3-4
pubmed: 24704295
Oncogene. 2003 Oct 13;22(45):7050-7
pubmed: 14557810
Dermatol Ther. 2014 May-Jun;27(3):148-52
pubmed: 24903471
Radiat Res. 2003 May;159(5):581-96
pubmed: 12710869
Environ Mol Mutagen. 2008 Jun;49(5):381-7
pubmed: 18418872